Absea Biotech

We organized a casual get-together for the biotech teams in our building — Meet Your New Neighbor.

Simple idea. The kind of thing you assume will happen eventually, until you just start it.

Food, drinks, good conversations.

Thanks to everyone who joined, already planning the next one!

🔗 absea.bio

CDH6, CDH17, CDH3 — from EMT textbooks to clinical-stage ADC programs in just a few years.

Translation is accelerating.
But the foundational question remains:
How is your target expressed in real patient tissue?
IHC still provides the answer.

We develop validated antibodies to support that work.👇

References:

1️⃣ www.mcponline.org/article/S153... (MCP) – ¹⁵N standards in proteomics workflows
2️⃣ www.nature.com/articles/s41... (Nature Genetics) – ¹⁵N for genetic/proteomic validation

Multi-site #proteomics studies require cross-lab consistency.

Fold-change comparisons can vary between sites.

¹⁵N-labeled full-length protein standards integrate before extraction and move through digestion and LC-MS, improving cross-site reproducibility and validation robustness.

#Biomarkers

We have a new biosafety cabinet.

Instead of calling movers, we moved it ourselves — across campus to our new lab at Campus Berlin-Buch GmbH.

Five hours.
Careful lifting.
A lot of hands.

And just like that, it’s in the lab.

#Biotech #LabLife

Custom #antibodies often fail in assays where they weren’t tested.

We provide hybridoma supernatants to test in your workflow before clone selection.

Sequenced antibodies remove hybridoma dependence.

4,700+ projects. 18–24 weeks. absea.bio

Paper Highlight: Tumor-reactive T cells aren't only tumor-resident—peripheral blood supplies them during checkpoint therapy.

Li et al. (Cell Stem Cell) GLI model captures this ex vivo. Our anti-LAMP3 KC-1563 identified mature DCs coordinating infiltration.

🔗 www.cell.com/cell-stem-ce...

We evaluate 100,000 protein construct variants computationally before any lab work.

It may sound excessive, but it consistently delivers ~75% success for soluble proteins.

ML-guided custom protein production. 4-8 week turnaround. 500/month capacity.

How it work👇

absea.bio

#Proteomics #Biotech

Solving Tau's plasma fragmentation hurdle 🧠

Fragments cleave ~123/224 → anchoring = sensitivity driver

Our pTau217/231/205 pairs deliver:

🔹 Peptide-scanned epitopes
🔹 Exon 4A exclusion (CNS-specific)
🔹 Endogenous validation (HEK293 overexpression lysates)

No more ghost signals 👻

absea.bio

The English version of our BuchInside feature is live! 🌐

Great for a deep dive into the Absea journey—from our Cambridge roots to our protein algorithms and our new home at the BerlinBioCube.

Our SVP Philip Lössl covers the "why" here: 🔗 www.campusberlinbuch.de/en/news/757e...

#Science

January.

Between setting up the new lab and onboarding our two newest technicians, it’s been a busy transition.
We finally stepped away from the new space last week to share a meal together, and enjoy a night away from the packing tape. 🥂

#ScienceSky #Biotech

Deep contrastive learning enables genome-wide virtual screening Recent breakthroughs in protein structure prediction have opened new avenues for genome-wide drug discovery, yet existing virtual screening methods remain computationally prohibitive. We present DrugC...

Link to the study: www.science.org/doi/10.1126/...

Screening the entire human druggable proteome in a single day.

New in @science.org: Absea SAB member Lei Liu and colleagues introduce DrugCLIP. The framework scored 10 trillion pairs in <24h, identifying 2M+ candidates across 20,000 pockets.

Link:👇

#ScienceSky #DrugDiscovery #Cheminformatics

Team expansion at Berlin! 🇩🇪

We are happy to welcome Janine Gebhard and Xueyang Peng as our newest technicians in Berlin.

They join the proteomics team led by Clément Potel, supporting end-to-end experimental workflows in our new labs. 🔬

Great to have you with us! #ScienceSky #Proteomics

Liver FFPE cyclic mIHC is demanding (autofluorescence + background).

Absea mAbs are developed & validated for compatibility with cyclic mIHC workflows.

KRT18/PIGR • CD3G/CD8A/AIF1 • CD9/SPP1

Interested to hear what’s worked best for others in liver FFPE cyclic mIHC.

#SciSky #IHC 🧬

Study link: www.nature.com/articles/s41...

How do lipid transfer proteins choose their cargo? 🧪

In Nature, our senior scientist Marco Hennrich (co-first + co-corresponding) and colleagues present a systematic, proteome-scale map of ~100 human LTPs. This work defines the general principles of lipid mobilization and species selectivity.
Link👇

Background binding, allele bias, low recovery—MHCII #immunopeptidomics is only as reliable as the antibody used.

At Absea®, we develop IP–MS-validated antibodies for HLA-DR, -DQ, and -DP to capture native #MHC II–peptide complexes with reproducibility.

Happy to discuss workflows. 🔬

A Novel Hybrid High-Speed Mass Spectrometer Allows Rapid Translation From Biomarker Candidates to Targeted Clinical Tests Using 15N-Labeled Proteins In BriefThe novel Stellar mass spectrometer bridges the gap between biomarker discovery and clinical implementation. By combining the robustness of triple quadrupole instruments with the enhanced capa...

For more on isotope-labeled protein standards, this MCP paper gives a good overview of isotope-labeled protein standards: www.mcponline.org/article/S153...

SILAC relies on metabolic labeling of proteins in cells and is most commonly applied for relative quantification between conditions, whereas here defined amounts of purified isotope‑labeled proteins are added as external standards to determine absolute protein abundances.

Full interview: www.campusberlinbuch.de/de/e/dct/129...

In a recent interview, our SVP Dr. Philip Lössl shared how we think about quantitative #proteomics at Absea.

Moving from peptide surrogates to full-length, isotope-labeled proteins supports absolute quantification and more interpretable data—particularly in translational research.

Interview link 👇

Absea Berlin is moving and scaling!

Double the team → double the space
Split offices → everyone together
Shared equipment → our own lab

Moving faster from early ideas to actual data.

📍New address:
Absea Biotechnology GmbH
Building D95 (BerlinBioCube)
Robert-Rössle-Str. 10
13125 Berlin, Germany

For validation data and reagent specifications: www.absea.bio/index.html
Or reach out directly: info@abseabio.com

#Lifesciences #AntibodyDevelopment #CancerResearch

Here's a pattern we kept seeing:

FGF2 heals wounds but drives tumor angiogenesis
FGF21 regulates fasting but is elevated in diabetes
FGF23 balances phosphate but causes CV issues in CKD

We validated antibody pairs for 8 FGF targets with Wellgrow Tech — flow cytometry + IHC, batch-tested

Contact👇

🎄 The holiday spirit is here at Absea!
Last night we celebrated a year of research, conferences, new ideas, and teamwork — and our Berlin team doubled in size along the way.
Thanks to everyone we’ve worked with, collaborated with, or learned from in 2025.
Wishing you all a great start to 2026!